ACADIA Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ACAD and other ETFs, options, and stocks.

About ACAD

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. 

CEO
Catherine Owen Adams
CEOCatherine Owen Adams
Employees
654
Employees654
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1993
Founded1993
Employees
654
Employees654

ACAD Key Statistics

Market cap
4.16B
Market cap4.16B
Price-Earnings ratio
15.91
Price-Earnings ratio15.91
Dividend yield
Dividend yield
Average volume
1.60M
Average volume1.60M
High today
$25.20
High today$25.20
Low today
$24.49
Low today$24.49
Open price
$25.04
Open price$25.04
Volume
1.44M
Volume1.44M
52 Week high
$28.35
52 Week high$28.35
52 Week low
$13.40
52 Week low$13.40

Stock Snapshot

ACADIA Pharmaceuticals(ACAD) stock is priced at $24.59, giving the company a market capitalization of 4.16B. It carries a P/E multiple of 15.91.

As of 2026-02-24, ACADIA Pharmaceuticals(ACAD) stock has fluctuated between $24.49 and $25.20. The current price stands at $24.59, placing the stock +0.4% above today's low and -2.4% off the high.

The ACADIA Pharmaceuticals(ACAD)'s current trading volume is 1.44M, compared to an average daily volume of 1.6M.

During the past year, ACADIA Pharmaceuticals(ACAD) stock moved between $13.40 at its lowest and $28.35 at its peak.

During the past year, ACADIA Pharmaceuticals(ACAD) stock moved between $13.40 at its lowest and $28.35 at its peak.

ACAD News

Simply Wall St 1d
Does ACADIA Have the Right Pipeline Mix as It Moves Beyond Nuplazid Dependence?

In recent days, ACADIA Pharmaceuticals drew fresh attention after Wall Street analysts reacted to updates on its neurology and rare‑disease pipeline, highlighti...

Does ACADIA Have the Right Pipeline Mix as It Moves Beyond Nuplazid Dependence?
TipRanks 2d
Acadia Pharmaceuticals upgraded to Outperform from Neutral at Mizuho

Mizuho upgraded Acadia Pharmaceuticals (ACAD) to Outperform from Neutral with a price target of $35, up from $29. The firm believes remlifanserin, which is in a...

Analyst ratings

71%

of 21 ratings
Buy
71.4%
Hold
23.8%
Sell
4.8%

People also own

Based on the portfolios of people who own ACAD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.